Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Humacyte Inc (NASDAQ: HUMA) closed at $1.07 down -0.93% from its previous closing price of $1.08. In other words, the price has decreased by -$0.93 from its previous closing price. On the day, 3.66 million shares were traded. HUMA stock price reached its highest trading level at $1.1 during the session, while it also had its lowest trading level at $1.04.
Ratios:
For a deeper understanding of Humacyte Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.90 and its Current Ratio is at 1.62.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on August 27, 2025, initiated with a Overweight rating and assigned the stock a target price of $3.50. H.C. Wainwright reiterated its Buy rating for the stock on December 20, 2024, while the target price for the stock was revised from $12 to $15.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 19 ’25 when Dougan Brady W sold 1,100,000 shares for $1.63 per share. The transaction valued at 1,793,000 led to the insider holds 591,685 shares of the business.
Dougan Brady W sold 549,360 shares of HUMA for $1,005,329 on Aug 18 ’25. The Director now owns 1,691,685 shares after completing the transaction at $1.83 per share. On Aug 20 ’25, another insider, Dougan Brady W, who serves as the Director of the company, sold 591,685 shares for $1.58 each. As a result, the insider received 934,862 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 200380336 and an Enterprise Value of 231863312. For the stock, the TTM Price-to-Sale (P/S) ratio is 131.54. Its current Enterprise Value per Revenue stands at 147.59 whereas that against EBITDA is -2.382.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.89, which has changed by -0.7897839 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $5.66, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -20.92%, while the 200-Day Moving Average is calculated to be -41.81%.
Shares Statistics:
For the past three months, HUMA has traded an average of 5.47M shares per day and 4896450 over the past ten days. A total of 193.00M shares are outstanding, with a floating share count of 163.06M. Insiders hold about 15.51% of the company’s shares, while institutions hold 23.96% stake in the company. Shares short for HUMA as of 1765756800 were 35398643 with a Short Ratio of 6.47, compared to 1763078400 on 33414650. Therefore, it implies a Short% of Shares Outstanding of 35398643 and a Short% of Float of 21.209998.
Earnings Estimates
. The current assessment of Humacyte Inc (HUMA) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.12 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.18 and -$0.58 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.53, with 4.0 analysts recommending between -$0.46 and -$0.67.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $3.94M. There is a high estimate of $5.85M for the next quarter, whereas the lowest estimate is $2.4M. Based on 6 analysts’ estimates, the company’s revenue will be $23.65M in the next fiscal year. The high estimate is $44.63M and the low estimate is $11.03M.
